Steven Skolsky
Director/Board Member at Elligo Health Research, Inc.
Net worth: 31 679 $ as of 2024-03-30
Profile
Steven D.
Skolsky currently works at Elligo Health Research, Inc., as Director, Kenan Flagler Business School Foundation, as Director, Quintiles Transnational Corp., as Global Head-Clinical & Data Operations from 2011, and Kenan-Flagler Business School, as Member-Foundation Board.
Mr. Skolsky also formerly worked at Trimeris, Inc., as Chief Executive Officer from 2004 to 2006, Sequoia Pharmaceuticals, Inc., as President & Chief Executive Officer from 2007 to 2009, Fennec Pharmaceuticals, Inc., as Independent Director, Clinipace, Inc., as Director from 2017 to 2021, NVN Liquidation, Inc., as Independent Director from 2021 to 2023, Quintiles Transnational Holdings, Inc., as Managing Director & Senior Vice President, Basilea Pharmaceutica AG, as Independent Non-Executive Director from 2010 to 2023, GlaxoSmithKline NZ Ltd., as Managing Director, GlaxoSmithKline Investments Pty Ltd., as Managing Director, GSK Plc, as VP-Global Product Strategy & Clinical Development from 2010 to 2011, Glaxo Wellcome, Inc., as Vice President-Sales & Marketing, and Expis Partners, as Principal.
Mr. Skolsky received his undergraduate degree from The University of North Carolina at Charlotte.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
BASILEA PHARMACEUTICA AG
0.01% | 2022-12-30 | 757 ( 0.01% ) | 31 643 $ | 2024-03-30 |
NVN LIQUIDATION INC
0.13% | 2023-06-06 | 36,101 ( 0.13% ) | 36 $ | 2024-03-30 |
Steven Skolsky active positions
Companies | Position | Start |
---|---|---|
Quintiles Transnational Corp.
Quintiles Transnational Corp. Miscellaneous Commercial ServicesCommercial Services Quintiles Transnational Corp. provides biopharmaceutical development and commercial outsourcing services. It offers product development and integrated healthcare services, including commercial and observational solutions. The company was founded by Dennis B. Gillings and Gary Koch in September 1990 and is headquartered in Durham, NC. | Corporate Officer/Principal | 2011-10-10 |
Kenan-Flagler Business School | Corporate Officer/Principal | - |
Elligo Health Research, Inc.
Elligo Health Research, Inc. Miscellaneous Commercial ServicesCommercial Services Elligo Health Research, Inc. provides clinical research services. It offers Direct approach and IntElligo Research Stack clinical technology ? a complete standards-based technology solution that delivers better patients and improved real-time data. The company was founded by John Gary Potthoff and Chad Moore on March 1, 2016 and is headquartered in Austin, TX. | Director/Board Member | - |
Kenan Flagler Business School Foundation | Director/Board Member | - |
Former positions of Steven Skolsky
Companies | Position | End |
---|---|---|
NVN LIQUIDATION, INC. | Director/Board Member | 2023-09-26 |
BASILEA PHARMACEUTICA AG | Director/Board Member | 2023-04-25 |
Clinipace, Inc.
Clinipace, Inc. Miscellaneous Commercial ServicesCommercial Services Clinipace, Inc. provides digital contract research solutions. The firm operates as a digital contract research organization that assists life science firms in developing and executing regulatory strategies, clinical development, and post-approval research. Its service areas encompass clinical monitoring, data management, medical affairs and writing, patient recruitment, study feasibility, and site selection and management. The company was founded by Ronald G. Marks, Christopher K. Porter, and Jeff Lewis Williams in 2003 and is headquartered in Morrisville, NC. | Director/Board Member | 2021-05-31 |
Quintiles Transnational Holdings, Inc.
Quintiles Transnational Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Quintiles Transnational Holdings, Inc. engages in biopharmaceutical development and commercial outsourcing. It operates through the Product Development and Integrated Healthcare Services segments. The Product Development segments provide project management and clinical monitoring, clinical trial support services, strategic planning and design, and consulting services. The Integrated Healthcare Services segments provide commercial services, communications and engagement services, real-world and late phase research, and other healthcare solutions. The company was founded by Dr. Gillings in 1982 and is headquartered in Durham, NC. | Chief Executive Officer | 2016-07-31 |
Sequoia Pharmaceuticals, Inc.
Sequoia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sequoia Pharmaceuticals discovers and develops unique treatments for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing global problem of drug-resistant disease. Most new anti-viral drugs were designed to block the most prevalent form of a pathogen, but these drugs become less potent due to the emergence of drug-resistant mutations. Sequoia's is to discover and develop new antiviral which are active against the most prevalent form of the virus but also anticipates the emergence of drug resistance forms thereby maintaining potency over time. Sequoia's differentiating approach is to identify a constellation of atomic interaction points which are necessary and sufficient for enzymatic function. Sequoia's protease inhibitors have been designed to interact preferentially with only these atoms, thus allowing non-critical mutations to occur without resulting in a decrease in drug potency. The foundation of Sequoia's novel Resistant-Repellent™ technology is a drug discovery tool that enhances the efficiency with which drugs are designed. It is based on an understanding of the chemical and physical nature of the molecular targets, the enzymes and receptors to which drugs bind, combined with an understanding of the molecular mechanisms that cause drug resistance. Sequoia is also discovering and developing a unique series of pharmacokinetic enhancers (PKEs) to work in combination with its own, and its partners', antiviral therapies. These sets of molecules improve the PK of existing therapeutics and reduce interpatient variability. This represents a unique approach to an important need in HIV treatment today. Sequoia is also looking to extend this novel PKE approach to other areas. Its PKEs are designed to inhibit a particular CYP isozyme and therefore change the metabolism of a co-administered therapeutic agent. The combination of PK Enhancer and the therapeutic agent enables reduced dosage and less frequent administration of the therapeutic agent. | Chief Executive Officer | 2009-11-30 |
Training of Steven Skolsky
The University of North Carolina at Charlotte | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 4 |
---|---|
FENNEC PHARMACEUTICALS INC. | Health Technology |
NVN LIQUIDATION, INC. | Health Technology |
GSK PLC | Health Technology |
BASILEA PHARMACEUTICA AG | Health Technology |
Private companies | 11 |
---|---|
Quintiles Transnational Corp.
Quintiles Transnational Corp. Miscellaneous Commercial ServicesCommercial Services Quintiles Transnational Corp. provides biopharmaceutical development and commercial outsourcing services. It offers product development and integrated healthcare services, including commercial and observational solutions. The company was founded by Dennis B. Gillings and Gary Koch in September 1990 and is headquartered in Durham, NC. | Commercial Services |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Health Technology |
Sequoia Pharmaceuticals, Inc.
Sequoia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sequoia Pharmaceuticals discovers and develops unique treatments for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing global problem of drug-resistant disease. Most new anti-viral drugs were designed to block the most prevalent form of a pathogen, but these drugs become less potent due to the emergence of drug-resistant mutations. Sequoia's is to discover and develop new antiviral which are active against the most prevalent form of the virus but also anticipates the emergence of drug resistance forms thereby maintaining potency over time. Sequoia's differentiating approach is to identify a constellation of atomic interaction points which are necessary and sufficient for enzymatic function. Sequoia's protease inhibitors have been designed to interact preferentially with only these atoms, thus allowing non-critical mutations to occur without resulting in a decrease in drug potency. The foundation of Sequoia's novel Resistant-Repellent™ technology is a drug discovery tool that enhances the efficiency with which drugs are designed. It is based on an understanding of the chemical and physical nature of the molecular targets, the enzymes and receptors to which drugs bind, combined with an understanding of the molecular mechanisms that cause drug resistance. Sequoia is also discovering and developing a unique series of pharmacokinetic enhancers (PKEs) to work in combination with its own, and its partners', antiviral therapies. These sets of molecules improve the PK of existing therapeutics and reduce interpatient variability. This represents a unique approach to an important need in HIV treatment today. Sequoia is also looking to extend this novel PKE approach to other areas. Its PKEs are designed to inhibit a particular CYP isozyme and therefore change the metabolism of a co-administered therapeutic agent. The combination of PK Enhancer and the therapeutic agent enables reduced dosage and less frequent administration of the therapeutic agent. | Health Technology |
Clinipace, Inc.
Clinipace, Inc. Miscellaneous Commercial ServicesCommercial Services Clinipace, Inc. provides digital contract research solutions. The firm operates as a digital contract research organization that assists life science firms in developing and executing regulatory strategies, clinical development, and post-approval research. Its service areas encompass clinical monitoring, data management, medical affairs and writing, patient recruitment, study feasibility, and site selection and management. The company was founded by Ronald G. Marks, Christopher K. Porter, and Jeff Lewis Williams in 2003 and is headquartered in Morrisville, NC. | Commercial Services |
Quintiles Transnational Holdings, Inc.
Quintiles Transnational Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Quintiles Transnational Holdings, Inc. engages in biopharmaceutical development and commercial outsourcing. It operates through the Product Development and Integrated Healthcare Services segments. The Product Development segments provide project management and clinical monitoring, clinical trial support services, strategic planning and design, and consulting services. The Integrated Healthcare Services segments provide commercial services, communications and engagement services, real-world and late phase research, and other healthcare solutions. The company was founded by Dr. Gillings in 1982 and is headquartered in Durham, NC. | Commercial Services |
Glaxo Wellcome, Inc. | Health Technology |
GlaxoSmithkline NZ Ltd.
GlaxoSmithkline NZ Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline NZ Ltd. is a pharmaceutical company that manufactures pharmaceutical products. The private company is based in Auckland, New Zealand. | Health Technology |
Glaxosmithkline Investments Pty Ltd.
Glaxosmithkline Investments Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline Investments Pty Ltd. is an Australian company. | Health Technology |
Elligo Health Research, Inc.
Elligo Health Research, Inc. Miscellaneous Commercial ServicesCommercial Services Elligo Health Research, Inc. provides clinical research services. It offers Direct approach and IntElligo Research Stack clinical technology ? a complete standards-based technology solution that delivers better patients and improved real-time data. The company was founded by John Gary Potthoff and Chad Moore on March 1, 2016 and is headquartered in Austin, TX. | Commercial Services |
Kenan Flagler Business School Foundation | |
Expis Partners |
- Stock Market
- Insiders
- Steven Skolsky